VPRIV® (velaglucerase alfa for injection) logo
Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
Important Safety Information: Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV should be administered under the supervision of a healthcare professional. Read more Important Safety Information

One-on-one product support

OnePath® patient access and support

personalized product support

personalized product support


OnePath provides eligible, enrolled patients, and caregivers with personalized product support.

As part of OnePath, a dedicated OnePath Patient Support Manager will work with you one-on-one. From helping to coordinate your first infusion to answering your insurance questions, your dedicated OnePath Patient Support Manager will be here to help you every step of the way.

Your OnePath Patient Support Manager can help by:

  • Facilitating a benefits investigation
  • Providing information about financial assistance options
  • Coordinating infusion appointments
  • Working with your specialty pharmacy
  • Identifying educational materials and resources

If VPRIV is the therapy you choose, you may decide to fill out a OnePath Start Form with your doctor. This will initiate your treatment and support from OnePath. You do not have to sign a Start Form to receive VPRIV therapy, but we will need the form in order for you to receive OnePath product support services. Read below for more information about the Start Form.

Getting Started

Work with your physician to sign and submit a OnePath Start Form, which can be downloaded below. Once completed, your physician should fax the Start Form to OnePath at 1-888-990-0008. A OnePath Patient Support Manager will call you when they receive the form and help to get you started on VPRIV.

Download the Start Form

Haz clic aquí por el formulario en Español

Contact OnePath® Patient Support Managers

Contact OnePath today to get started.

OnePath® Patient Support Managers are available from 8:30am - 8:00pm (ET) at 1-866-888-0660.

Visit OnePath.com
Download the OnePath® patient app

Bringing support to your mobile device.

Download the OnePath® patient app to your mobile device.




VPRIV® (velaglucerase alfa for injection) is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.


  • Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV should be administered under the supervision of a healthcare professional. VPRIV is given every other week by intravenous infusion that typically takes up to 60 minutes. Appropriate medical support should be available when VPRIV is administered. The most serious side effects in patients treated with VPRIV were hypersensitivity reactions.
  • Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.
  • If anaphylactic or other acute reactions occur, your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.
  • The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.
  • Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
  • The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.
  • The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.
  • As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.
  • Please see full Prescribing Information.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You are about
to leave this site.

You are being directed to another site.

Please be advised that Shire may not have control over the content or presentation of the site you are about to view.

Back Continue

You are about
to leave this site.

You are being directed to another site.

The information contained in this section of the site is intended for US health care professionals only. Click Continue if you are a health care professional.

Back Continue